A bipartisan group of lawmakers is pressuring the U.S. Department of Health and Human Services (HHS) to intervene in an ongoing dispute between Eli Lilly and hospitals participating in a federal drug discount program. The lawmakers contend that Eli Lilly’s recent decision to withhold mandated drug discounts from hospitals that do not provide specific claims data violates federal law.
Why Lawmakers Are Challenging Eli Lilly
The core of the dispute centers on a federal drug discount program, an initiative that requires pharmaceutical manufacturers to provide outpatient drugs to eligible hospitals and clinics at significantly reduced prices.
The drugmaker stopped offering discounts last month to reduce what it calls duplicate discounts paid to the hospitals. Eli Lilly targeted 50 larger hospital systems among approximately 1,000 hospitals that had not complied with a new policy that was announced this year. The company maintained that roughly 70% of the hospitals that participate in the discount program, or more than 2,300, had previously provided claims data. A bipartisan group of lawmakers argued in a letter to Department of Health and Human Services Secretary Robert F. Kennedy Jr. that Lilly is failing to comply with federal law by eliminating the price breaks.
The Conflict Over Claims Data
Eli Lilly maintains that its data-sharing requirement is a measure to ensure program integrity. The company reports that approximately 70% of the more than 2,300 hospitals participating in the discount program have already complied with the request to provide claims data.
However, the opposing lawmakers assert that Lilly is failing to comply with federal law. The letter sent to HHS Secretary Robert F. Kennedy Jr. urges the administration to enforce compliance.
Impact on Hospital Systems
The 50 hospital systems targeted by Eli Lilly’s policy represent a portion of the landscape.
| Feature | Eli Lilly Position | Hospital/Lawmaker Position |
|---|---|---|
| Data Requirement | Necessary to prevent duplicate discounts. | Failing to comply with federal law. |
| Program Integrity | Claims data ensures compliance. | Violates federal law. |
| Current Scope | Affects ~50 hospital systems. | Failing to comply with federal law. |
What Happens Next
The dispute now rests with the Department of Health and Human Services.
The bipartisan letter serves as a formal request for the administration to force Eli Lilly to reinstate mandated price breaks.